JP2006502171A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502171A5 JP2006502171A5 JP2004535464A JP2004535464A JP2006502171A5 JP 2006502171 A5 JP2006502171 A5 JP 2006502171A5 JP 2004535464 A JP2004535464 A JP 2004535464A JP 2004535464 A JP2004535464 A JP 2004535464A JP 2006502171 A5 JP2006502171 A5 JP 2006502171A5
- Authority
- JP
- Japan
- Prior art keywords
- diseases
- substance
- disorders
- certain
- iritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0220953.4A GB0220953D0 (en) | 2002-09-10 | 2002-09-10 | Organic compounds |
| PCT/EP2003/010007 WO2004024714A1 (en) | 2002-09-10 | 2003-09-09 | Aroyl-piperidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006502171A JP2006502171A (ja) | 2006-01-19 |
| JP2006502171A5 true JP2006502171A5 (https=) | 2006-10-26 |
| JP4564846B2 JP4564846B2 (ja) | 2010-10-20 |
Family
ID=9943781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004535464A Expired - Fee Related JP4564846B2 (ja) | 2002-09-10 | 2003-09-09 | アロイル−ピペリジン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7678814B2 (https=) |
| EP (1) | EP1539737A1 (https=) |
| JP (1) | JP4564846B2 (https=) |
| CN (1) | CN1681803A (https=) |
| AU (1) | AU2003273398A1 (https=) |
| BR (1) | BR0314164A (https=) |
| CA (1) | CA2498285C (https=) |
| GB (1) | GB0220953D0 (https=) |
| WO (1) | WO2004024714A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0220953D0 (en) * | 2002-09-10 | 2002-10-23 | Novartis Ag | Organic compounds |
| CN101668527A (zh) * | 2007-02-23 | 2010-03-10 | 阿韦拉制药股份有限公司 | 药物制剂 |
| WO2013004766A1 (en) | 2011-07-04 | 2013-01-10 | Ferrari Giulio | Nk-1 receptor antagonists for treating corneal neovascularisation |
| US20210015834A1 (en) | 2018-02-26 | 2021-01-21 | Ospedale San Raffaele S.R.L. | Nk-1 antagonists for use in the treatment of ocular pain |
| WO2021180885A1 (en) | 2020-03-11 | 2021-09-16 | Ospedale San Raffaele S.R.L. | Treatment of stem cell deficiency |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6115A (ja) * | 1984-06-12 | 1986-01-06 | Kyowa Hakko Kogyo Co Ltd | リポキシゲナ−ゼ代謝産物に起因する疾患の予防治療剤 |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| TW397825B (en) | 1994-10-14 | 2000-07-11 | Novartis Ag | Aroyl-piperidine derivatives |
| TW475930B (en) | 1995-04-24 | 2002-02-11 | Novartis Ag | Novel compound, its use and pharmaceutical composition comprising it |
| AU2898297A (en) | 1996-05-24 | 1998-01-05 | Novartis Ag | Use of substance p antagonists for treating social phobia |
| AR018376A1 (es) | 1998-05-26 | 2001-11-14 | Novartis Ag | Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento |
| JP4510290B2 (ja) | 1998-08-25 | 2010-07-21 | ノバルティス アーゲー | 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用 |
| KR20030027016A (ko) * | 2000-08-09 | 2003-04-03 | 에프. 호프만-라 로슈 아게 | 항-염증제로서의 퀴놀린 유도체 |
| JP2002220386A (ja) * | 2000-10-02 | 2002-08-09 | Tanabe Seiyaku Co Ltd | ベンジルアミン誘導体、その製法およびその合成中間体 |
| GB0220953D0 (en) * | 2002-09-10 | 2002-10-23 | Novartis Ag | Organic compounds |
-
2002
- 2002-09-10 GB GBGB0220953.4A patent/GB0220953D0/en not_active Ceased
-
2003
- 2003-09-09 WO PCT/EP2003/010007 patent/WO2004024714A1/en not_active Ceased
- 2003-09-09 EP EP03755553A patent/EP1539737A1/en not_active Withdrawn
- 2003-09-09 CA CA2498285A patent/CA2498285C/en not_active Expired - Fee Related
- 2003-09-09 AU AU2003273398A patent/AU2003273398A1/en not_active Abandoned
- 2003-09-09 BR BR0314164-0A patent/BR0314164A/pt not_active IP Right Cessation
- 2003-09-09 US US10/527,518 patent/US7678814B2/en not_active Expired - Fee Related
- 2003-09-09 CN CNA038212552A patent/CN1681803A/zh active Pending
- 2003-09-09 JP JP2004535464A patent/JP4564846B2/ja not_active Expired - Fee Related
-
2010
- 2010-01-20 US US12/690,210 patent/US8193218B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200628472A (en) | Piperidinylamino-thieno (2,3-d) pyrimidine compounds | |
| MY147442A (en) | Imidazoquinolines as lipid kinase inhibitors | |
| UA99309C2 (ru) | Замещенные пиперидинодигидротиенопиримидины | |
| NO20050164L (no) | Nye quinuklidin-amid-derivater | |
| NO20074615L (no) | Dihydrotienopyrimidiner for behandling av inflamatoriske sykdommer | |
| RS52526B2 (sr) | Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 | |
| JP2005527593A5 (https=) | ||
| EA200802051A1 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| EA200601160A1 (ru) | 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов | |
| NO20083562L (no) | Cannabinoidreseptormodulatorer | |
| JP2005506370A5 (https=) | ||
| EA200100124A1 (ru) | Замещенные 1,8-нафтиридин-4(1h)-оны в качестве ингибиторов фосфодиэстеразы 4 | |
| WO2009003868A3 (en) | 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) | |
| DE502005010170D1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
| US20180078548A1 (en) | Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors | |
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| JP2006502171A5 (https=) | ||
| JP2007516278A5 (https=) | ||
| NO20074617L (no) | Nye forbindelser for behandling av inflamotoriske sykdommer | |
| WO2005105092A3 (en) | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity | |
| JP2005527477A5 (https=) | ||
| JP2008516909A5 (https=) | ||
| WO2009078432A1 (ja) | １-アルキル-４-アミノ-１ｈ-ピラゾール-３-カルボキサミド化合物 | |
| MX2010009403A (es) | Derivados de 2-aminoquinolina. | |
| ATE399164T1 (de) | Antagonisten des opioidrezeptors |